Skip to content
Screener

Arcus Biosciences RCUS R&D services — Total revenues

Other product segments

License
$4M

Similar metrics at other companies

Veeva Systems logo
VEEVR&D and Quality Solutions — Total revenues
$95.2M+22.5%
Kinetik Holdings logo
KNTKService revenue — Total revenues
$93.77M-26.7%
Agilon Health logo
AGLMedical services revenue — Total revenues
$1.49B+7.2%
InnovAge Holdings, Inc. logo
INNVOther service revenue — Total revenues
$441K+36.5%
GE Vernova logo
GEVServices — Total revenues
$4.65B+10.1%
PowerFleet, Inc. logo
AIOTServices — Total revenues
$92.94M+13.7%

Other financials

Income statement

See full
Revenue$41.0M-74.4%
Operating income-$96.0M-1,100%
Net income-$91.0M
EPS (diluted)-$0.72

Balance sheet

See full
Cash & equivalents$150.0M-39.5%
Total debt$114.0M+4.6%
Total equity$464.0M-15.5%
Total assets$924.0M-14.0%

Cash flow

See full
Operating cash flow-$119.0M+10.5%
CapEx-
Free cash flow-$119.0M+10.5%

Valuation

See full
Market cap$3.61B+259%
Enterprise value$3.57B+312%
P/S30.8×+27.0×

Profitability

See full
Operating margin-415.4%-756pp
Net margin-393.2%-663pp
FCF margin-406%

Returns & leverage

See full
Return on equity-90.8%+373pp
Debt / equity0.2×0.0×
Current ratio3.8×-0.7×

Where this comes from

Reported directly by Arcus Biosciences in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001724521-26-000044
Line itemOver timePoint in timeThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Gilead Collaboration
License and development services*$8$152$15$172
R&D services*4265
Access rights*2162411
Other*3
Taiho Collaboration
License and development services*46
License*44

Item 1. Financial Statements

FAQ

What is Arcus Biosciences's R&D services — total revenues?
Arcus Biosciences (RCUS) reported R&D services — total revenues of $4M in Q2 2026.
How has Arcus Biosciences's R&D services — total revenues changed year-over-year?
Arcus Biosciences's R&D services — total revenues increased by 100.0% year-over-year, from $2M to $4M.
What does R&D services — total revenues mean?
This metric represents the total gross revenue recognized from research and development service activities provided to external partners or collaborators. It reflects the company's ability to monetize its scientific expertise and infrastructure by performing specialized clinical or laboratory work for third parties. This revenue stream serves as a key indicator of the company's external service-based business model and its ability to generate non-dilutive capital through collaborative research efforts.

Ask your AI about Arcus Biosciences's r&d services — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude